Press Release
15 Mar, 2021
87
InnoCare to Hold 2021 R&D Day on April 15, 2021
3332
11 Mar, 2021
55
InnoCare to Host 2020 Full Year Earnings Call on March 29, 2021
3327
05 Feb, 2021
127
Beijing, Feb. 5, 2021 —— InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that China National Medical Products Administration (NMPA) has approved the clinical trial of Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib in combination with R-CHOP for previously untreated patients with mantle cell lymphoma (MCL).
3306